Xmetix

Company Overview

Snapshot

Founded in April 2019 by Irad Kuhnreich and Eviatar Kuhnreich, Xmetix operates with 1–10 employees. The company has secured funding across two rounds from NGT HealthCare II and NGT3, with its most recent funding round occurring in October 2024.

Business overview

Xmetix is at the forefront of revolutionizing battlefield and emergency medicine through its development of smart tactical garments. The company's core product, the TAK710, is an automated tourniquet designed to eliminate human error in critical bleeding control situations. This proprietary technology, backed by multiple patents, provides rapid, reliable, and adjustable hemorrhage control. Xmetix serves military units, first responders, and civilian markets, operating within the Aerospace, Defense & HLS, and Health Tech & Life Sciences sectors.

Company Intelligence Q&A

What is Xmetix's primary product?

Xmetix's primary product is the TAK710, an automated tourniquet designed for rapid and reliable hemorrhage control in battlefield and emergency medicine, eliminating human error with one-button activation and precise pressure control.

When was Xmetix founded and by whom?

Xmetix was founded in April 2019 by co-founders Irad Kuhnreich, who serves as CTO, and Eviatar Kuhnreich, who is the.

Which markets does Xmetix primarily serve?

Xmetix primarily serves the Americas, Asia, and Europe, targeting military, first responders, and civilian users with its tactical medical devices.

What is the strategic focus of Xmetix's technology?

Xmetix's strategic focus is on developing proprietary technology, such as the TAK710 automated tourniquet, to improve survival rates and optimize long-term patient outcomes by providing rapid and reliable hemorrhage control in critical situations.